跳至主要内容
临床试验/DRKS00025479
DRKS00025479招募中不适用

Analysis/Outcomes of Patients who switched from being under eculizumab to ravulizumab treatment in a real-world setting – according to the label but not included in Phase 3 studies - RavuReWo

Alexion Pharma Deutschland GmbH0 个研究点目标入组 30 人开始时间: 2021年10月29日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Patient is = 18 years at time of switch to ravulizumab
  • Diagnosis of PNH established by flow cytometry
  • Patient was pretreated with eculizumab and data from treatment with eculizumab are available
  • Willingness to participate in the study and provide written informed consent
  • Participant is currently receiving or starting treatment with ravulizumab treatment in accordance with the SmPC
  • Patient experienced HDA within 6 months of eculizumab treatment prior to switch to ravulizumab, with HDA defined as hemolysis (LDH = 1.5 x ULN) in combination with = 1 of the following PNH symptoms:
  • oHemoglobinuria
  • oAbdominal pain
  • oAnemia [< 10 g/dl],
  • oMAVEc [including thrombosis],
  • oErectile dysfunction
  • oPNH related transfusion

排除标准

  • Unwillingness / anticipated inability to attend further visits
  • Off-label treatment with ravulizumab

研究者

发起方
Alexion Pharma Deutschland GmbH

相似试验